Leveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness

Abstract

In chimeric antigen receptor (CAR) T-cell therapies, T cells from patients are reprogrammed to target their tumor cells. This is done using viral vectors to insert the CAR gene into the T-cell genome. While many heavily pretreated patients show response and CAR T-cell expansion, others do not. Our findings suggest that the CAR genes’ insertion location can influence clinical effectiveness by altering cellular genes. However, the biology of many insertion sites is still not fully understood. This review presents current insights into the link between vector integration and CAR T-cell efficacy.